Shire Pharmaceuticals Schedules Conference Call and Webcast to Discuss First Quarter 2001 Financial Results

Apr 19, 2001, 01:00 ET from Shire Pharmaceuticals Group plc

    BASINGSTOKE, United Kingdom, April 19 /PRNewswire/ -- Shire
 Pharmaceuticals Group plc ("Shire") (Nasdaq:   SHPGY; London: SHP.L) announced
 today that it will release first quarter 2001 financial results for the period
 ended March 31, 2001 on Thursday, April 26, 2001.
     Management will conduct a conference call to be broadcast live,
 simultaneously over the Internet to review the Company's quarterly results.
 Rolf Stahel, President and Chief Executive, Angus Russell, Group Finance
 Director and Wilson Totten MD, Group R&D Director, will host the call.
     The conference call is scheduled for 10:30 AM (EDT), 9:30 AM (CST),
 7:30 AM (PCT), and 3:30 PM (GMT) on Thursday, April 26, 2001.  Individuals
 wishing to participate can access the live audio webcast of Shire's quarterly
 and year-end conference call through www.streetfusion.com . To access the
 visual webcast presentation, go to Shire Pharmaceutical Group's website at
 www.shire.com .
     Shire is an international specialty pharmaceutical company with a
 strategic focus on four therapeutic areas: central nervous system disorders,
 metabolic diseases, oncology and gastroenterology. The Group has a sales and
 marketing infrastructure with a broad portfolio of products, with its own
 direct marketing capability in the US, Canada, UK, Republic of Ireland,
 France, Germany, Italy and Spain and with plans to add Japan by 2004. Shire
 also covers other significant pharmaceutical markets indirectly through
 distributors and sales coverage continues to grow.
     Shire's global search and development expertise has to date successfully
 provided eight marketed products, of which Reminyl(TM) for the treatment of
 Alzheimer's disease has recently been launched in the UK, its first market in
 Europe. The National Institute of Clinical Excellence (NICE) recommended on
 January 19, 2001 that treatment for Alzheimer's disease be made available
 through the National Health Service (NHS) in the UK. Additionally, on
  February 28, 2001 Reminyl(TM) received Food and Drug Administration (FDA)
 approval to be marketed in the US. The current pipeline of 17 projects
 includes three projects in registration in various countries, plus the
 delivery of the first regulatory submission for Foznol(TM) to a Reference
 Member State in the EU Mutual Recognition Procedure on March 13, 2001, and 6
 others that are post Phase II. Shire is actively seeking to acquire further
 marketed products and development projects to enhance the potential for future
 growth. Shire's M&A activity has resulted in five completed mergers and
 acquisitions during the last six years.
     On December 11, 2000, Shire entered into an agreement to merge with
 BioChem Pharma Inc. to form a leading global specialty pharmaceutical company.
 More details on this proposed merger and other aspects of the company are
 available on the Shire website at http://www.shire.com .
 
     The "Safe Harbor" Statement Under the Private Securities Litigation Reform
 Act of 1995. The statements in this press release that are not historical
 facts are forward-looking statements that involve risks and uncertainties,
 including but not limited to, risks associated with the inherent uncertainty
 of pharmaceutical research, product development and commercialisation, the
 impact of competitive products, patents, and other risks and uncertainties,
 including those detailed from time to time in periodic reports, including the
 F-4 Prospectus and the Annual Report filed on Form 10K by Shire with the
 Securities and Exchange Commission.
 
 

SOURCE Shire Pharmaceuticals Group plc
    BASINGSTOKE, United Kingdom, April 19 /PRNewswire/ -- Shire
 Pharmaceuticals Group plc ("Shire") (Nasdaq:   SHPGY; London: SHP.L) announced
 today that it will release first quarter 2001 financial results for the period
 ended March 31, 2001 on Thursday, April 26, 2001.
     Management will conduct a conference call to be broadcast live,
 simultaneously over the Internet to review the Company's quarterly results.
 Rolf Stahel, President and Chief Executive, Angus Russell, Group Finance
 Director and Wilson Totten MD, Group R&D Director, will host the call.
     The conference call is scheduled for 10:30 AM (EDT), 9:30 AM (CST),
 7:30 AM (PCT), and 3:30 PM (GMT) on Thursday, April 26, 2001.  Individuals
 wishing to participate can access the live audio webcast of Shire's quarterly
 and year-end conference call through www.streetfusion.com . To access the
 visual webcast presentation, go to Shire Pharmaceutical Group's website at
 www.shire.com .
     Shire is an international specialty pharmaceutical company with a
 strategic focus on four therapeutic areas: central nervous system disorders,
 metabolic diseases, oncology and gastroenterology. The Group has a sales and
 marketing infrastructure with a broad portfolio of products, with its own
 direct marketing capability in the US, Canada, UK, Republic of Ireland,
 France, Germany, Italy and Spain and with plans to add Japan by 2004. Shire
 also covers other significant pharmaceutical markets indirectly through
 distributors and sales coverage continues to grow.
     Shire's global search and development expertise has to date successfully
 provided eight marketed products, of which Reminyl(TM) for the treatment of
 Alzheimer's disease has recently been launched in the UK, its first market in
 Europe. The National Institute of Clinical Excellence (NICE) recommended on
 January 19, 2001 that treatment for Alzheimer's disease be made available
 through the National Health Service (NHS) in the UK. Additionally, on
  February 28, 2001 Reminyl(TM) received Food and Drug Administration (FDA)
 approval to be marketed in the US. The current pipeline of 17 projects
 includes three projects in registration in various countries, plus the
 delivery of the first regulatory submission for Foznol(TM) to a Reference
 Member State in the EU Mutual Recognition Procedure on March 13, 2001, and 6
 others that are post Phase II. Shire is actively seeking to acquire further
 marketed products and development projects to enhance the potential for future
 growth. Shire's M&A activity has resulted in five completed mergers and
 acquisitions during the last six years.
     On December 11, 2000, Shire entered into an agreement to merge with
 BioChem Pharma Inc. to form a leading global specialty pharmaceutical company.
 More details on this proposed merger and other aspects of the company are
 available on the Shire website at http://www.shire.com .
 
     The "Safe Harbor" Statement Under the Private Securities Litigation Reform
 Act of 1995. The statements in this press release that are not historical
 facts are forward-looking statements that involve risks and uncertainties,
 including but not limited to, risks associated with the inherent uncertainty
 of pharmaceutical research, product development and commercialisation, the
 impact of competitive products, patents, and other risks and uncertainties,
 including those detailed from time to time in periodic reports, including the
 F-4 Prospectus and the Annual Report filed on Form 10K by Shire with the
 Securities and Exchange Commission.
 
 SOURCE  Shire Pharmaceuticals Group plc